In parallel, dual-targeting strategies that integrate metabolic inhibition with PD-1/PD-L1 or CTLA-4 blockade are under investigation in multiple cancer types, including non-small cell lung cancer, hepatocellular carcinoma, and ovarian cancer. Here, CTLA4 is linked to cancer.